Latest Breaking News On - Elderly relapsed - Page 3 : comparemela.com

Actinium to Showcase First-In-Class Targeted Radiotherapies in Two Presentations at the 2023 AACR Annual Meeting

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies,.

United statesSandesh sethHans vitzthumClinical research excluding trialsAmerican association for cancer researchLifesci advisorsLg chem companyActinium pharmaceuticals incActinium pharmaceuticalsAmerican associationCancer researchChief executiveClinical research excludingImmunomodulatory agentsTuesday aprPoster section

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMadhuri vusirikalaCaroline yarbroughSandesh sethVenetoclax bclSergio giraltAvinash desaiDivision of hematologic malignanciesService at memorial sloan kettering cancer centerActinium pharmaceuticals incEuropean medicines agencyHans vitzthumlifesci advisorsCommittee for medicinal products human useClinical developmentFred hutchinson cancer research centerPrnewswire actinium pharmaceuticals inc

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

- Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical.

United statesMadhuri vusirikalaCaroline yarbroughSandesh sethHans vitzthumVenetoclax bclSergio giraltAvinash desaiLifesci advisorsActinium pharmaceuticals incDivision of hematologic malignanciesService at memorial sloan kettering cancer centerClinical developmentComplete remissionActinium pharmaceuticalsInvestor conference call

Actinium Pharmaceuticals, Inc to Present at the 3rd Annual B Riley Securities Oncology Conference

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today.

Hans vitzthumExchange commissionActinium pharmaceuticals incLifesci advisorsPrnewswire actinium pharmaceuticals incSecurities oncologyRiley securitiesAnnual oncologyAnnual oncology conferenceActinium pharmaceuticalsElderly relapsedRefractory acute myeloid leukemiaLooking statementsSci advisors

Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, today.

United statesNew orleansSameem abedinHans vitzthumAvinash desaiExchange commissionAmerican society of hematologyErnestm morial convention centerLifesci advisorsActinium pharmaceuticals incProfessor at froedtert medical college wisconsinCollege of wisconsinOverall survivalAmerican societyAnnual meetingActinium pharmaceuticals